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Background/aim: This study aims to determine the therapeutic superiority of the addition of intratympanic steroid or hyperbaric
oxygen therapy to systemic steroid treatment in idiopathic sudden sensorineural hearing loss as initial treatment, and evaluate the longterm results of salvage treatment.
Materials and methods: This study was a retrospective clinical trial with a total of 96 patients with idiopathic sudden sensorineural
hearing loss. Patients were divided into 3 groups. Group 1 (n: 32) received systemic steroid treatment. Group 2 (n: 32) received the
Group 1 protocol plus intratympanic steroid treatment. Group 3 (n: 32) received the Group 1 protocol plus hyperbaric oxygen treatment.
Pretreatment and postinitial audiologic evaluations were performed, and the hearing outcome was analyzed with Furuhashi criteria. All
patients, except those who experienced total recovery after initial treatment, were directed to salvage treatment. Audiologic assessment
was performed again after salvage treatment and a mean follow-up period of 36.5 months.
Results: Each group was homogenous according to demographics, audiologic data, and prognostic factors. There was no statistically
significant difference in recovery and success rate within the 3 groups after initial treatment. (P: 0.66, P: 0.248, respectively). Successful
results were obtained after salvage treatment in only 3 patients (5%). These patients received follow-up treatment at a mean of 36.5
months, but there was no spontaneous recovery after the end of salvage treatment.
Conclusion: The addition of intratympanic steroids or hyperbaric oxygen to systemic steroids caused no significant hearing improvement
as the initial treatment of idiopathic sudden sensorineural hearing loss. The efficacy of salvage treatment was limited, and there was no
spontaneous hearing improvement after the long-term follow-up.
Key words: Idiopathic sudden sensorineural hearing loss, systemic steroid treatment, hyperbaric oxygen therapy, intratympanic steroid
treatment, salvage treatment

1. Introduction
Idiopathic sudden sensorineural hearing loss (ISSHL) is
an infrequent otologic emergency which is defined as loss
of more than 30 dB in at least 3 contagious frequencies
within 3 days. Up-to-date ISSHL etiology, pathogenesis,
and treatment have not been clarified exactly. Systemic
steroids (SS) are the most frequently used treatment
modality that has been investigated in several clinical trials
[1,2]. There are still controversies in administration route,
dosage, duration of therapy, and selection of corticosteroid
type. After the first attempt of intratympanic steroid (ITS)
usage in inner ear disease in 1991, 3 different protocols

of ITS usage in ISSHL have been developed: initial
monotherapy, initial adjunctive to SS, and salvage therapy.
However, the best dosage, type, and timetable are still
unclear today [3,4]. Hyperbaric oxygen therapy (HBOT),
which is frequently used as an alternative modality to
steroids in the treatment of ISSHL, diminishes cochlear
hypoxia, edema, and damage. Efficacy in ISSHL treatment
is still controversial but is generally accepted as salvage
therapy [5–7].
To get superior therapeutic results, combination
modalities, such as the addition of ITS or HBOT to
SS, have been tried by many authors, but various and
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conflicting results have been obtained [2,8–11]. Thus, Gau
and Liu performed a metaanalysis with 8 studies about the
addition of ITS to SS [12]. They reported better outcomes
in pure tone threshold average (PTTA) scores, particularly
in severe-profound hearing loss patients, with the addition
of ITS. There are also 2 systematic reviews in the literature
that were performed with 19 and 16 trials of the addition
of HBOT to SS. Both of them recommended the addition
of HBOT to SS, especially in severe-profound hearing loss
[13,14].
In the literature, most of the studies compared the
success rates of SS monotherapy with either ITS or HBOT.
Only 2 studies compared the addition of ITS and HBOT
to SS. Sukuzi et al. [15] concluded that the combination
of ITS and SS was superior to the addition of HBOT in
terms of recovery rate. However, Toroslu et al. [16] found
no significant differences between the 2 combination
protocols. Thus, we conducted this study firstly, to show the
therapeutic superiority of the ITS or HBOT combination
as initial therapy, and secondly, to exhibit the short-term
and the long-term prognosis after the salvage treatment of
the ISSHL patients.
2. Materials and methods
This clinical study with ISSHL patients was conducted in
a tertiary referral center after the approval of local ethics
committee (No: 42/13:06.11.2017) The recordings of these
patients who were managed with different treatment
protocols between 2012 and 2016 were evaluated
retrospectively.
2.1. Inclusion criteria
1. Patients who were hospitalized due to ISSHL with a
symptom duration of fewer than 30 days.
2. Patients who completed the treatment protocols
properly.
3. Patients who have the recordings of the pretreatment
and
posttreatment
audiogram,
otolaryngologic
examination, and magnetic resonance imaging with
contrast.
2.2. Exclusion criteria
1. Symptom duration of longer than 30 days.
2. Previous history of Meniere’s disease, acoustic
trauma, chronic otitis media, cerebellopontine angle
pathologies, ototoxic drug usage, ISSHL, or otologic
surgery.
3. Bilateral ISSHL.
4. Newly diagnosed vestibular schwannoma.
5. Patients who were referred to our clinic after starting
medication.
Patient characteristics including age, sex, affected
ear side, presence of vertigo and tinnitus symptoms,
history of systemic illness such as diabetes mellitus and
hypertension, upper respiratory tract disease history, and
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time duration between the onset of symptoms and therapy
were evaluated.
According to the inclusion and exclusion criteria, the
patients were divided into 3 groups for initial treatment.
Group 1 was the steroid monotherapy group, and the
treatment consisted of SS plus 5 mg/kg of intravenous
dextran for 5 days, plus 3 × 1600 mg oral piracetam till the
end of therapy. Methylprednisolone was used as a single
bolus dosage of 250 mg for the first day, 150 mg for the
second day, and 100 mg for the third day. After the third
day, 1 mg/kg/d oral methylprednisolone was started and
tapered 16 mg every 3 days. Those in Group 2o received
the Group 1 treatment protocol, plus simultaneously 5
doses of 2 mg of intratympanic dexamethasone (0.5 mL
from 4 mg/ml ampul form) once every 2 days. Those in
Group 3 received the Group 1 treatment protocol plus 120
min of 2.5-atmosphere HBOT for 20 consecutive days.
Pretreatment and posttreatment audiologic tests were
analyzed. Speech discrimination scores (SDS) were noted,
and PTTA was calculated as the average of thresholds at
0.5, 1, 2, and 4 kHz. Posttreatment improvement of PTTA
results were analyzed according to Furuhashi criteria [17]
(Table 1).
The clinical records of the patients without complete
recovery who were directed to salvage treatment were
also analyzed. Group 1 patients were treated with ITS
protocol and then HBOT if there was no complete
recovery. In Group 2 and Group 3 patients, HBOT and
ITS protocols were added as salvage, respectively. The preand postsalvage audiograms were compared. Finally, the
last audiologic data of the patients after the follow-up were
examined and compared with the postsalvage results.
2.3. Statistical analyses
Statistical analyses were performed with IBM SPSS
22.0 for Windows (IBM Corp., Armonk, NY, USA).
Numerical variables were summarized as mean ± standard
deviation or median (minimum–maximum). Categorical
variables were given as frequencies and percentages.
Categorical variables were compared by chi-square test.
Normality of the continuous variables was evaluated by
the Kolmogorov-Smirnov test. Homogeneity of variances
was tested by Levene test. Differences between the groups
according to continuous variables were determined by
one-way ANOVA or Kruskal–Wallis test as appropriate. A
P-value of less than 0.05 was considered significant.
3. Results
The study group was composed of 96 patients. All 3
groups had 32 patients each. Patient characteristics
including age, sex, affected ear side, presence of vertigo
and tinnitus symptoms, history of systemic illness such
as diabetes mellitus and hypertension, upper respiratory
tract disease history, and time duration between onset of
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symptoms and therapy are shown in Table 2. According to
these characteristics, there was no statistically significant
difference, so there was no heterogeneity in each group.
The groups were also investigated according to
pretreatment audiologic data. The level of hearing loss of
each patient was categorized according to initial PTTA
at 500, 1000, 2000, and 4000 Hz, and classified as mild
(26–40 dB), moderate (41–60 dB), severe (61–80 dB),
and profound (>80 dB) hearing loss. Also, PTTA and SDS
were calculated in each group. All groups were statistically
homogenous concerning initial audiologic assessment,
which is shown in Table 3.
The audiologic evaluation after initial treatment was
evaluated, and PTTA of all patients in each groups was
categorized according to Furuhashi criteria. The results
are shown in Table 4. There was no statistically significant
difference in posttreatment audiologic results between
the groups (P: 0.66). Complete recovery and marked
improvement were accepted as successful treatment, and
was the result for 24 (75%), 18 (56,3%), and 19 (59.4%)
patients in Groups 1, 2, and 3, respectively. There was no
significant difference between groups (P: 0.248) (Table 5).
The overall success rate was 63.5%, and the overall complete
recovery rate after initial treatment was 50%, regardless of

the type of treatment regimens in all 96 patients.
The patients without complete recovery (n: 48, 50%)
were directed to salvage therapy. Only 40 of these patients’
audiologic results were available at the end of salvage
treatment. Presalvage and postsalvage PTTA results were
evaluated, and the patients were categorized according to
Furuhashi criteria. Only 3 of the patients (2 patients with
complete recovery, 1 patient with marked improvement)
out of 40 (7.5%) obtained successful results after salvage
treatment. Thus, the success rate was 58% after the
completion of the initial treatment and salvage treatment
in 88 patients. The audiograms of these 40 patients were
reanalyzed with a mean of 36.5 (±18.61) months of
follow-up after the end of salvage treatment. There was
no statistically significant difference in PTTA between
presalvage and postsalvage or between postsalvage and
long-term follow-up (P: 0.121, P: 0.223, respectively)
(Table 6). The long-term follow-up spontaneous recovery
rate after the salvage therapy with a mean follow-up of 36.5
months was 0%.
4. Discussion
Due to the lack of proven definitive etiopathogenetic
mechanisms in ISSHL, no standard 100% curative

Table 1. Furuhashi criteria for the assessment of audiologic hearing outcome.
Criteria
Complete recovery

PTTA <20 dB or identical to contralateral nonaffected ear

Marked improvement

PTTA improvement >30 dB

Slight improvement

PTTA improvement between 10 and 30 dB

No recovery

PTTA improvement <10 dB

PTTA: Pure tone threshold average (500, 1000, 2000, and 4000 Hz)
Table 2. Patient characteristics of Groups 1, 2, and 3.
Group 1
(n: 32)

Group 2
(n: 32)

Group 3
(n: 32)

P- value

Age (mean ± standard deviation)

45.81 ± 19.45

48.62 ± 15.39

43.31 ± 12.32

0.322

Sex (male/female)

25/7

20/12

18/14

0.165

Side (right/left)

12/20

18/14

12/20

0.218

Presence of vertigo (yes/no)

6/26

3/29

5/27

0.542

Presence of tinnitus (yes/no)

24/8

22/10

21/11

0.708

Presence of diabetes mellitus (yes/no)

5/27

8/24

4/28

0.395

Presence of hypertension (yes/no)

8/24

9/23

4/28

0.278

Presence of upper respiratory tract infection (yes/no)

2/30

2/30

3/29

0.862

Time interval between onset of symptom and therapy
(days) (mean ± standard deviation)

4.5 ± 4.52

5.22 ± 3.3

4.09 ± 4.02

0.079
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Table 3. Pretreatment audiologic assessment of Groups 1, 2, and 3.
Group 1
(n: 32)

Group 2
(n: 32)

Group 3
(n: 32)

Ascending

11

9

12

Flat or deaf

18

17

16

Descending

3

6

4

Mild

13

5

4

Moderate

7

10

12

Severe

4

8

7

Profound

8

9

9

Pretreatment PTTA (dB) (mean ± standard deviation)

57.44 ± 30.37

66.09 ± 25.06

66.37 ± 24.63

0.321

Pretreatment SDS (%) (mean ± standard deviation)

60.5 ± 37.6

48.62 ± 32.16

48.87 ± 31.82

0.089

P-value

Audiogram shape (number of patients)
0.805

Pretreatment degree of hearing loss (n)

0.153

PTTA: Pure tone threshold average (500, 1000, 2000, and 4000 Hz)
dB: Decibels, SDS: Speech discrimination score
Table 4. Posttreatment categorization according to Furuhashi criteria.
Number of patients (%)

Group 1

Group 2

Group 3

Complete recovery

19 (59.4%)

14 (43.8%)

15 (46.9%)

Marked improvement

5 (15.6%)

4 (12.5%)

4 (12.5%)

Slight improvement

3 (9.4%)

8 (25%)

5 (15.6%)

No recovery

5 (15.6%)

6 (18.7%)

8 (25%)

Total

32

32

32

P-value

0.66

Table 5. Results of successful treatment after initial therapy in Groups 1, 2, and 3.
Group 1

Group 2

Group 3

Successful* (Patient no. %)

24 (75%)

18 (56.3%)

19 (59.4%)

Unsuccessful (Patient no. %)

8 (25%)

14 (43.7%)

13 (40.6%)

Total

32

32

32

P-value
0.248

* Successful criteria: Total number of patients in complete recovery and marked improvement
groups according to Furuhashi criteria.

treatment modality has been established yet. The recovery
rate of patients with ISSHL, regardless of therapy regimens,
was shown to be up to 89% [18]. There are several
prognostic factors influencing the hearing outcome. In
addition to the type of treatment protocol, success also
depends on age, presence of tinnitus, initial hearing level,
smoking, the shape of audiometry curve, and the time
interval between the onset of symptoms and the beginning
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of therapy [19–21]. Furthermore, there is still a lack of
consensus in evaluation criteria of hearing outcome. Pure
tone audiometry threshold levels in dB values, SDS, or
categorizations according to hearing improvement such as
Furuhashi criteria are generally used for hearing outcome
assessment [22]. Another point to mention is that there
are still no uniform standards in dosage and duration of
protocols, regardless of any sort of therapy. Because of
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Table 6. Comparison of presalvage, postsalvage, and long-term follow-up
PTTA.
Mean

Standard deviation

Presalvage PTTA

70.56

24.77

Postsalvage PTTA

65.14

24.60

Long-term follow-up PTTA

68.52

24.43

P-value
0.121
0.223

PTTA: Pure tone threshold average (500, 1000, 2000, and 4000 Hz)

these reasons, different and conflicting results are found
in the literature. Although Cinamon et al. [23] found
that there were no significant difference in recovery rate
between groups receiving SS treatment and a placebo,
Wilson et al. [24] reported significant improvement of SS
over a placebo. In our study, the groups were homogenous
according to prognostic factors, and the complete recovery
rate was the highest in the SS monotherapy group (59.4%
vs. 43.8% and 46.9%). In Group 1, better but insignificant
pretreatment PTTA and SDS levels may have led to higher
success rates compared to the other groups.
Systemic usage of steroids has some limitations due
to serious side effects such as peptic ulcer, glaucoma,
uncontrolled diabetes mellitus, hypertension, osteoporosis,
and avascular necrosis of the femur. So, the intratympanic
route has become popular both in salvage and initial
treatment of ISSHL. Successful results were shown by
several studies in both initial treatment and salvage
therapy after SS [18,24–27]. In the present study, ITS in
combination with SS as an initial treatment resulted in a
complete recovery rate of 43.8%. In the literature, initial
ITS treatment in ISSHL has a success rate range between
55% and 80% [28]. The recommended time duration
between symptom onset and ITS therapy to best improve
the outcome is fewer than 10 days [22]. Although our
mean duration of initiation of ITS therapy was 5.2 days,
we weren’t able to achieve better results with the addition
of ITS. The addition of ITS to SS has revealed different
results in the literature. Battaglia et al. [25] and Gundogan
et al. [29] reported better hearing improvement in ITS in
combination with SS according to PTTA. On the other
hand, Baysal et al. [30] and Koltsidopoulos et al. [31]
concluded no superior hearing improvement of ITS in
combination with SS.
The usage of HBOT as an initial treatment of ISSHL
was investigated by several authors. Cekin et al. [32] and
Alimoglu et al. [33] compared HBOT plus oral steroids
with treatment by oral steroids alone retrospectively and
found no significant differences between them. Topuz
et al. [5] and Fujimura et al. [34] reported significant
improvement in hearing outcome with HBOT as the
initial treatment of ISSHL. Thus there is still controversy

about the effectiveness of HBOT in initial management.
Our study showed that the addition of HBOT to SS as
initial treatment did not result in better hearing outcome
compared to SS monotherapy.
There are only 2 studies comparing ITS in combination
with HBOT to SS as an initial treatment in the literature.
Suzuki et al. [15] compared 174 patients who received
ITS plus SS with 102 patients who received HBOT plus
SS, retrospectively. The total recovery (cure) rate was
29.3% and 21.6% with the combination of ITS and HBOT,
respectively, which was not statistically significantly
different. Although the group sizes were much larger than
in our study, the groups were not homogenous according
to initial hearing level and presence of vertigo, and there
was no control group receiving SS monotherapy. They
concluded that the addition of ITS probably leads to a
higher recovery rate than the addition of HBOT. Toroslu et
al. [16] analyzed the combination of ITS and HBOT with
SS with 90 patients retrospectively. The study consisted of
4 groups: Group 1 received oral steroids, Group 2 received
oral steroids and ITS, Group 3 received oral steroids and
HBOT, and Group 4 received ITS. The overall complete
recovery rate of all 90 patients was 32.2%, which was
lower than in our study. They compared the mean hearing
gain in dB instead of the recovery rate. There was no
statistically significant difference in hearing gain within
subgroups. Our result was similar to the aforementioned
2 studies in that neither ITS nor HBOT in addition to SS
had a superior recovery rate in ISSHL as initial treatment.
It is important to establish the clinical progress and
long-term prognosis of ISSHL. Intratympanic steroids
and HBOT are commonly used as salvage treatment
after SS therapy failure and various results have been
reported [20,35]. Most of the patients recover within the
first month of therapy [36,37]. In a retrospective study,
delayed recovery (21.8%) occurred after the first month
of discharge, and the complete recovery rate was 4.6%
[37]. In our study, the complete recovery rate after salvage
therapy was 5% (2 patients). As hearing recovery generally
occurs within the first month of therapy, treatment should
be done within the first 30 days to gain maximal hearing
outcome. Although the salvage group size (40 patients)
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was not large enough, the present study showed that there
were no significant spontaneous recovery or deterioration
in PTTA after the salvage treatment with a mean followup of 36.5 months.
This study has some limitations. Due to the low
incidence of ISSHL, the number of patients in this
retrospective study was not large enough, and there was
no placebo subgroup. Secondly, a smoking habit, which
is a poor prognostic factor, was not evaluated in patient
characteristics. Thirdly, there was no hearing outcome
analysis with respect to pretreatment hearing loss degree.
Lastly, posttreatment levels of SDS and frequency-specific
pure tone thresholds and mean hearing gain in dB were
not evaluated in the assessment of outcome.
In conclusion, the addition of ITS or HBOT to SS
for ISSHL as initial treatment did not cause statistically
significant therapeutic superiority and improvement.
Furthermore, the efficacy in hearing improvement
of salvage treatment in ISSHL is still limited. No
spontaneous recovery occurs after the end of salvage

treatment during long-term follow-up. Thus, for ISSHL
and many inner ear diseases, the cochlea is still a
mysterious locked box of which definitive pathogenesis
has not been clearly explored yet. Between several types
of treatment modalities, only steroids and hyperbaric
oxygen were shown to be effective in ISSHL. Yet there
is no alternative treatment protocol superior to these.
New regimens should be introduced after clarification of
definitive etiopathogenesis by the help of studies in the
future.
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